Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), filed a Form 4 on September 21, 2026, disclosing a stock option exercise and the sale of 6,018 shares of common stock on September 17, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Hohl exercised a stock option for 3,982 shares of common stock at an exercise price of $14.85 per share on September 17, 2026.
  • Shares sold: A total of 6,018 shares were sold across three separate transactions on September 17, 2026, at weighted average prices of $50.0286, $50.7158, and $51.4929.
  • Post-transaction ownership: Following all reported transactions, Hohl directly held 38,000 shares of common stock, with certain shares representing restricted stock units (RSUs).
  • Rule 10b5-1 plan: All transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Hohl on March 18, 2026.
  • Remaining option position: After the exercise, Hohl holds 181,018 shares underlying a stock option with an exercise price of $14.85 and an expiration date of February 13, 2034.
  • Original option grant: The option was originally granted for 185,000 shares, with one-fourth vesting on February 13, 2025, and the remainder vesting in 36 equal monthly installments thereafter.

Enliven Therapeutics CFO Reports Option Exercise and Multi-Tranche Share Sales

According to the filing, Benjamin Hohl, serving as Chief Financial Officer of Enliven Therapeutics, Inc., executed a stock option exercise and a series of common stock sales on September 17, 2026. Hohl acquired 3,982 shares through the exercise of a stock option at $14.85 per share (transaction code M). All activity was conducted under a Rule 10b5-1 trading plan that Hohl adopted on March 18, 2026, as disclosed in the filing's explanatory notes.

The filing reports three separate sale transactions on the same date. Hohl disposed of 3,535 shares at a weighted average price of $50.0286 (with individual trade prices ranging from $49.31 to $50.30), 2,194 shares at a weighted average price of $50.7158 (ranging from $50.31 to $51.26), and 289 shares at a weighted average price of $51.4929 (ranging from $51.365 to $51.70). Following all transactions, Hohl directly owned 38,000 shares of common stock, with the filing noting that certain of these securities are RSUs, each representing a contingent right to receive one share of common stock subject to applicable vesting conditions.

With respect to the derivative security position, the filing states that the stock option originally covered 185,000 shares, with one-fourth vesting on February 13, 2025, and the remainder vesting in 36 equal monthly installments after that date. After the 3,982-share exercise reported here, 181,018 shares remain underlying the option, which carries an expiration date of February 13, 2034. The filing indicates the price of the derivative security as $0 in connection with the exercise transaction.

What Was Disclosed

Enliven Therapeutics CFO Benjamin Hohl disclosed a stock option exercise of 3,982 shares at $14.85 and the sale of 6,018 total shares at weighted average prices between $50.0286 and $51.4929 on September 17, 2026, all under a pre-established Rule 10b5-1 plan.